...Diagnostic play T2 Biosystems (NASDAQ:TTOO) named Maurice Castonguay CFO. Castonguay was SVP and CFO of Sonus...

...complete the review of SNUS's NDA for EchoGen emulsion ultrasound contrast agent. (SNUS earnings, B14) Sonus Pharmaceuticals Inc....

...determined that it will regulate all contrast agents as drugs (see BioCentury Extra, July 30). Sonus Pharmaceuticals Inc....

...of the company's shares to OncoGenex's original shareholders as part of its merger agreement with Sonus Pharmaceuticals Inc....

...to 27 $26.0 NA 6/30/08 NA Cuts primarily early stage R&D following the merger with Sonus...

...as SVP of regulatory affairs, formerly SVP of regulatory affairs/quality assurance and clinical research at Sonus Pharmaceuticals Inc....

...is formulated with the vitamin E-based Tocosol drug delivery system through its August merger with Sonus Pharmaceuticals Inc....

...OncoGenex and Sonus completed their previously announced merger to form OncoGenex Pharmaceuticals Inc. The combined company...
...expected to last until 1Q09 (see BioCentury, June 2). OncoGenex Technologies Inc. , Vancouver, B.C. Sonus Pharmaceuticals Inc....

...received an exclusive, worldwide license to preclinical caspase activators from Bayer’s Bayer Healthcare LLC unit. Sonus...
...compounds for cancer. Bayer retains rights to develop the non-core compounds for all other indications. Sonus...
...front and is eligible for undisclosed milestones, plus royalties. Further financial terms were not disclosed. Sonus Pharmaceuticals Inc....

...for solid tumors (see BioCentury, March 21 & May 2, 2005). OncoGenex is merging with Sonus Pharmaceuticals Inc....